We investigated the prognostic significance of mutation to the TP53 tumor suppressor gene in a series of 908 breast cancer patients treated with or without adjuvant therapies. The frequency of TP53 mutation detected by single strand conformation polymorphism (SSCP) was 19.4% (176/908) in the overall tumor series. In multivariate analysis, TP53 mutation was independently associated with worse survival in the overall (HR = 2.1, 95% CI [1.5-3.1], P < 0.0001), non-adjuvant treated (HR = 2.2, 95% CI [1.2-4.2], P = 0.017) and adjuvant treated (HR = 2.0, 95% CI [1.3-3.1], P = 0.0009) patients.

, , , , , ,
doi.org/10.1023/A:1012233509663, hdl.handle.net/1765/70480
Breast Cancer Research and Treatment
Department of Medical Oncology

Powell, B., Bydder, S., Grieu, F., Gnanasampanthan, G., Elsaleh, H., Seshadri, R., … Iacopetta, B. (2001). Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Research and Treatment, 69(1), 65–68. doi:10.1023/A:1012233509663